People · Operator

Ellen Strahlman

Named in public records as an officer, director or promoter · active 2025–2025 · Pharmaceuticals

1
Companies
1
Filings
$66.0M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Eyenovia, Inc.PharmaceuticalsSeries C$66.0M$312.6M2025
Operator network

Ellen Strahlman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Ernest Mario · 9 companies · 1 sharedErnest MarioAnthony Sun · 8 companies · 1 sharedAnthony SunCurt LaBelle · 7 companies · 1 sharedCurt LaBelleBARRY BUTLER · 6 companies · 1 sharedBARRY BUTLERFRED ESHELMAN · 5 companies · 1 sharedFRED ESHELMANTsontcho Ianchulev · 5 companies · 1 sharedTsontcho IanchulevCharles Mather · 2 companies · 1 sharedCharles MatherFredric Eshelman · 2 companies · 1 sharedFredric EshelmanJohn Gandolfo · 2 companies · 1 sharedJohn GandolfoKenneth Lee · 2 companies · 1 sharedKenneth LeeMichael Rowe · 2 companies · 1 sharedMichael RoweRachel Jacobson · 2 companies · 1 sharedRachel JacobsonHyunsu Jung · 1 companies · 1 sharedHyunsu JungMichael Geltzeiler · 1 companies · 1 sharedMichael GeltzeilerSHUHEI YOSHIDA · 1 companies · 1 sharedSHUHEI YOSHIDAEyenovia, Inc. · $66.0M raisedEyenovia, Inc.Ellen StrahlmanES
Ellen Strahlman Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Ellen Strahlman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Ernest Mario19
Anthony Sun18
Curt LaBelle17
BARRY BUTLER16
FRED ESHELMAN15
Tsontcho Ianchulev15
John Gandolfo12
Charles Mather12
Kenneth Lee12
Fredric Eshelman12
Rachel Jacobson12
Michael Rowe12
Michael Geltzeiler11
SHUHEI YOSHIDA11
Hyunsu Jung11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.